Home / Health / Lilly's Next-Gen Obesity Drug Shows Stunning Weight Loss
Lilly's Next-Gen Obesity Drug Shows Stunning Weight Loss
13 Oct
Summary
- Retatrutide achieved 28.3% average weight loss in a trial.
- Lilly aims for FDA submission of retatrutide in early 2027.
- Second-quarter revenue surged 48%, driven by Mounjaro and Zepbound.
Eli Lilly is advancing its next-generation obesity treatment, retatrutide, a once-weekly injection targeting three key hormone receptors involved in appetite, blood sugar, and metabolism.
Recent Phase 3 trial results presented in July showed impressive average weight loss figures, with patients achieving up to 28.3% reduction over 80 weeks in one study. Another trial involving patients with type 2 diabetes reported an average weight loss of up to 20.8%.
While retatrutide improved cardiovascular risk factors, further studies are needed to confirm its impact on major cardiovascular events. Lilly plans to seek FDA approval for retatrutide in the first quarter of 2027.
Meanwhile, Eli Lilly's current blockbuster diabetes and obesity drugs, Mounjaro and Zepbound, are fueling rapid growth. The company reported a 48% year-over-year revenue increase in the second quarter, largely due to demand for these medications. The upcoming third-quarter earnings report on October 29 will likely focus on these established sales.
